6. GOS (galactooligosaccharide)
Lactose-derived prebiotic on the HMO template — selective bifidogenic in infants and adults, mixed IBS data.
GOS in 1 minute
What does it provide? Galacto-oligomers (β(1→4) and β(1→6) linked galactose units with terminal glucose, DP 2–8) produced from lactose via β-galactosidase enzyme (transgalactosylation). Main components: galactobiose, allolactose, β-1,4-galactosyl-lactose, higher-DP oligomers. Partially mimics the bifidogenic effect of human milk oligosaccharides (HMO) — hence its inclusion in infant formula. In adulthood, Davis LM et al. Int J Food Microbiol 2010 RCT showed 5 g/day GOS for 3 weeks significantly raised Bifidobacterium proportion.
How much? Start with 2.5–3.5 g/day (½ tsp), titrate to 5–10 g/day over 1–2 weeks. Clinical documentation: 5.5 g/day Bifidobacterium-raising, 7–8 g/day in IBS context (Silk 2009 Aliment Pharmacol Ther) also has anxiolytic effect. GI tolerance threshold for gas/bloating ≈ 10–15 g/day.
When to avoid? Active IBS elimination phase (high FODMAP — GOS), active SIBO, severe lactose intolerance (GOS supplements may contain small residual lactose), milk-protein allergy (some manufacturers may have milk-protein contamination — label check needed), infant-formula use as home "supplementation" without medical oversight, simultaneous high-dose use of other fructan/GOS sources (FOS, inulin).
The history of galactooligosaccharides begins with the discovery of human milk oligosaccharides (HMO): in the 1950s, French chemists Polonowski and Lespagnol described that breast milk has orders of magnitude higher oligosaccharide content than cow's milk, and these complex galacto-glycans play a key role in shaping the infant gut flora (notable proportion: Bifidobacterium infantis). In the second half of the 20th century, Wallenfels and Malhotra's β-galactosidase enzyme research (1960s) revealed that GOS mixtures could be produced from lactose via enzymatic transgalactosylation.
Industrial GOS production has operated since the 1980s: the Japanese Yakult and Nissin Sugar, and the Finnish Friesland Campina (Vivinal GOS) were pioneers. Boehm et al. (2002, J Pediatr Gastroenterol Nutr) published the first RCT demonstrating that GOS+FOS 9:1 mix in infant formula mimics the bifidogenic effect of breast milk — this became the foundation of the HMO-mimic concept. Today, most infant formulas contain 0.4–0.8 g/100 ml GOS+FOS mix. In the adult clinical context, Davis 2010 (microbiota) and Silk 2009 (IBS) RCTs established the evidence base.
Scientific Background
GOS (galactooligosaccharide) is an oligomer built from galactose units with β(1→4) and β(1→6) linkages, often with a terminal glucose (lactose origin). DP 2–8 range; the most important components: galactobiose (Gal-Gal, DP 2), allolactose (β1,6-Gal-Glc, DP 2), β-1,4-galactosyl-lactose (Gal-Gal-Glc, DP 3), higher-DP oligomers. Industrial production: from lactose via β-galactosidase transgalactosylation (Bacillus circulans, Kluyveromyces lactis enzyme sources). Therefore some GOS supplements contain small residual lactose (1–10%) — important for lactose intolerance or milk-protein allergy categorization.
Bifidogenic effect — HMO mimic. Human milk oligosaccharides (HMO) have complex galacto-glycan structures (lactose core, fucosylated and sialylated forms), and selectively multiply Bifidobacterium infantis / B. longum subspecies. GOS partially mimics this selective bifidogenic effect — although structurally SIMPLER than HMO. Boehm 2002, Moro 2006 RCTs in infant-formula context showed: GOS+FOS (9:1) yields Bifidobacterium proportions and stool pH approaching that of breast milk.[2140][2143]
Adult microbiome RCT. Davis LM, Martínez I, Walter J, Hutkins R. Int J Food Microbiol 2010;144(2):285–292 placebo-controlled RCT in healthy adults: 5–10 g/day GOS for 3 weeks significantly raised Bifidobacterium (≈ 5-fold relative abundance increase at high dose) and decreased Bacteroides proportion.[2137] Dose-response was linear in the 0–10 g range.
IBS — mixed evidence. Silk 2009 Aliment Pharmacol Ther placebo-controlled RCT in IBS patients: 3.5–7 g/day GOS for 12 weeks significantly improved global IBS symptoms and anxiety scale, alongside Bifidobacterium increase.[2138] CONVERSELY: the Monash FODMAP system classifies GOS as high FODMAP, to be avoided during IBS elimination phase. The explanation: at low, targeted dose (3.5–7 g) it can be prebiotic therapy; at high dose from random dietary GOS (e.g., legumes) it is symptom-triggering.
Immunomodulation / allergy. Arslanoglu 2008 J Nutr RCT in infant-formula context showed reduced atopic dermatitis incidence by age 2 in infants fed GOS+FOS.[2141] Other studies confirm (Vandenplas 2020), although evidence is heterogeneous.
Mental health — gut-brain. Schmidt 2015 Psychopharmacology RCT in healthy adults: 5.5 g/day GOS for 3 weeks reduced morning cortisol response and improved emotion-recognition task results — a small but interesting "gut-brain" signal.[2139]
GI tolerance. Slavin 2013 Nutrients states GOS tolerance threshold is ≈ 10–15 g/day in a single dose.[879] Infant tolerance: well tolerated up to 0.8 g/100 ml. In adults, 5–10 g/day is the clinically documented range.
Regulatory status. FDA: GRAS self-affirmation + GRN letters (Vivinal GOS GRN 285, 484).[2144] EU: infant formula additive approved; health claim (prebiotic) not approved. EFSA: infant-formula safety recognized.
- + Live yogurt, kefir, Bifidobacterium-containing probiotic: synbiotic pattern — substrate + live strain.
- + Slow titration (2.5 g → 5 g → 7 g, 1–2 weeks per step): GI tolerance.
- + Psychological stress context (gut-brain): 5.5 g/day for cortisol modulation (Schmidt 2015).
- + IBS-D context low-dose targeted therapy (3.5–7 g, medical supervision): Silk 2009 documented.
- + Ample fluid intake: general fiber rule.
- + Other soluble fiber (psyllium) with slow titration: broader SCFA profile.
- Other high-FODMAP fibers (FOS + inulin + agave fructan) simultaneously in large doses: cumulative gas/bloating.
- Active IBS flare (elimination phase): avoid (except targeted low-dose therapy).
- Milk-protein allergy + non-milk-protein-free GOS: label check needed.
- Severe lactose intolerance + large-dose GOS: residual lactose may cause symptoms.
- Abrupt start at 10+ g/day without titration: uncomfortable bloating.
- ⚠️ IBS elimination phase: strictly avoid (high FODMAP GOS).
- Active SIBO flare: fermentation overload.
- Active UC/Crohn's flare: medical supervision.
- Severe lactose intolerance: due to residual lactose.
- Milk-protein allergy (confirmed): evaluate per product (milk-protein-free forms exist).
- Infants (home supplementation): only in medical/nutritional-specialist context.
- Galactosemia (inherited enzyme deficiency): absolute contraindication.
- Hereditary fructose intolerance HFI (mistaken confusion with fructan fibers): GOS itself is not at issue, but the mix-up is common.
- Severe bloating sensitivity: PHGG or gum arabic is a better option.
References
[879] Slavin J. Fiber and prebiotics: mechanisms and health benefits2013;5(4):1417–1435. Nutrients. Link
Review article in Nutrients on fiber and prebiotics, discussing their mechanisms of action and health benefits.
[2137] Davis LM, Martínez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults2010;144(2):285–292. Int J Food Microbiol. Link
The goal of this research was to determine the effect of different doses of galactooligosaccharide (GOS) on the fecal microbiota of healthy adults, with a focus on bifidobacteria. The study was designed as a single-blinded study, with eighteen subjects consuming GOS-containing chocolate chews at four increasing dosage levels; 0, 2.5, 5.0, and 10.0g. Subjects consumed each dose for 3 weeks, with a two-week baseline period preceding the study and a two-week washout period at the end. Fecal samples were collected weekly and analyzed by cultural and molecular methods. Cultural methods were used for bifidobacteria, Bacteroides, enterobacteria, enterococci, lactobacilli, and total anaerobes; culture-independent methods included denaturing gradient gel electrophoresis (DGGE) and quantitative real-time PCR (qRT-PCR) using Bifidobacterium-specific primers. All three methods revealed an increase in bifidobacteria populations, as the GOS dosage increased to 5 or 10g.
[2138] Silk DB et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome2009;29(5):508–518. Aliment Pharmacol Ther. Link
BACKGROUND: Gut microflora-mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (IBS). AIM: To investigate the efficacy of a novel prebiotic trans-galactooligosaccharide in changing the colonic microflora and improve the symptoms in IBS sufferers. METHODS: In all, 44 patients with Rome II positive IBS completed a 12-week single centre parallel crossover controlled clinical trial. Patients were randomized to receive either 3.5 g/d prebiotic, 7 g/d prebiotic or 7 g/d placebo. IBS symptoms were monitored weekly and scored according to a 7-point Likert scale. Changes in faecal microflora, stool frequency and form (Bristol stool scale) subjective global assessment (SGA), anxiety and depression and QOL scores were also monitored.
[2139] Schmidt K et al. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers2015;232(10):1793–1801. Psychopharmacology. Link
Study in healthy volunteers examining the effect of prebiotic intake on the waking cortisol response and emotional bias.
[2140] Boehm G et al. Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of faecal bifidobacteria in preterm infants2002;86(3):F178–F181. Arch Dis Child Fetal Neonatal Ed. Link
BACKGROUND: The establishment of a balanced intestinal microflora which may protect against infection is desirable for the preterm infant. OBJECTIVE: To investigate the effect of a preterm formula milk supplement consisting of oligosaccharides in similar proportions to human milk on the faecal flora and stool characteristics of preterm infants. STUDY DESIGN: To resemble the effect of human milk, an oligosaccharide mixture consisting of 90\% galacto-oligosaccharides and 10\% fructo-oligosaccharides was used to supplement a standard preterm formula at a concentration of 10 g/l. This supplemented formula was studied in 15 preterm infants, and the results were compared with those found in 15 infants fed a formula supplemented with maltodextrin as placebo. A group fed fortified mother's milk was investigated as a reference group (n = 12). On four days during a 28 day feeding period (1, 7, 14, and 28), the faecal flora was investigated, and stool characteristics, growth, and possible side effects were recorded.
[2141] Arslanoglu S et al. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life2008;138(6):1091–1095. J Nutr. Link
A mixture of neutral short-chain galactooligosaccharides (scGOS) and long-chain fructooligosaccharides (lcFOS) has been shown to reduce the incidence of atopic dermatitis (AD) and infectious episodes during the first 6 mo of life. This dual protection occurred through the intervention period. The present study evaluated if these protective effects were lasting beyond the intervention period. In a prospective, randomized, double-blind, placebo-controlled design, healthy term infants with a parental history of atopy were fed either a prebiotic-supplemented (8 g/L scGOS/lcFOS) or placebo-supplemented (8 g/L maltodextrin) hypoallergenic formula during the first 6 mo of life. Following this intervention period, blind follow-up continued until 2 y of life. Primary endpoints were cumulative incidence of allergic manifestations.
[2143] Vandenplas Y et al. Oligosaccharides in infant formula: more evidence to validate the role of prebiotics2020. Br J Nutr. Link
The gastrointestinal (GI) microbiota differs between breast-fed and classic infant formula-fed infants. Breast milk is rich in prebiotic oligosaccharides (OS) and may also contain some probiotics, but scientific societies do not recommend the addition of prebiotic OS or probiotics to standard infant formula. Nevertheless, many infant formula companies often add one or the other or both. Different types of prebiotic OS are used in infant formula, including galacto-oligosaccharide, fructo-oligosaccharide, polydextrose and mixtures of these OS, but none adds human milk OS. There is evidence that the addition of prebiotics to infant formula brings the GI microbiota of formula-fed infants closer to that of breast-fed infants. Prebiotics change gut metabolic activity (by decreasing stool pH and increasing SCFA), have a bifidogenic effect and bring stool consistency and defecation frequency closer to those of breast-fed infants.
[2144] . FDA GRN 285, 484 — Vivinal GOS GRAS no-questions letters. Link
FDA GRAS no-questions letters (GRN 285, 484) on Vivinal GOS.